Grant will partially fund research to enable faster development, with a higher probability of success, of new plant-based compounds (precision botanics) for the benefit of BioHarvest’s CDMO customers and partners July 15, 2026 - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that the Israel Innovation Authority (IIA) has approved a 4.33 million NIS (approximately USD $1.4 million) g

A year after emerging from stealth, Draig Therapeutics has closed an oversubscribed $65-million series B that will go toward accelerating its neuropsychiatric drug pipeline, with depression treatment DT-101 leading the charge. DT-101 is a positive allosteric modulator of the AMPA receptor that is being evaluated for major depressive disorder (MDD). The drug is currently being studied in two Phase II trials: a global study assessing DT-101 as monotherapy and a US study testing it in the adjunct

Funding to advance MindRank’s AI-native drug R&D engine and innovative pipeline, including MDR-001, an oral small-molecule GLP-1 receptor agonist in Phase III clinical development in China July 09, 2026 -- MindRank AI Ltd. (“MindRank”), a clinical-stage biotechnology company dedicated to building an AI-native engine for drug research and development, today announced the completion of a $52 million Series B financing. The round was led by a group of institutional and healthcare funds. MindRank

Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. The financing will scale manufacturing, accelerate commercial deployment

Additional capital brings total raised to $150 million in a Series C financing Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinic

MeiraGTx has secured an investment of up to $400 million from Oberland Capital to help get its late-stage gene therapies across the commercialization finish line. Earlier this year, MeiraGTx bought back botaretigene sparoparvovec (bota-vec) from Johnson & Johnson, despite the therapy failing to improve vision-guided mobility in patients with X-linked retinitis pigmentosa (XLRP) in a phase 3 trial . Despite the trial miss, the company touted “clinically meaningful benefit” seen in the data and s

Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestones July 07, 2026 --- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that it has entered into a securities purchas

July 7, 2026 -- Healome Therapeutics ("Healome"), a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, has closed a GBP£2 million oversubscribed seed financing round led by Empirical Ventures, with participation from DEBRA Research, Cure EB, Oshen Bio and existing investor SFC Capital. Proceeds will support pre-clinical development, manufacturing scale-up, regulatory engagement with the MHRA and FDA, and progression toward first-in-h

Financing brings together a syndicate of top-tier healthcare investors, including RA Capital Management, Leaps by Bayer, and Celea founder PureTech Health, alongside a large, US-based healthcare-focused fund and a leading sovereign wealth fund Proceeds will enable early Q3 2026 initiation of SURPASS-IPF, the first head-to-head Phase 3 trial in IPF, evaluating superiority of deupirfenidone vs. pirfenidone Celea Therapeutics ("Celea" or the "Company"), a clinical-stage biopharmaceutical company d

PureTech launches Celea as an independent company backed by a syndicate of top-tier healthcare investors, enabling PureTech’s transition to a lean operating model PureTech retains 35.4% ownership of Celea in addition to non-dilutive royalties, milestone payments, and sublicense income, maintaining long-term potential upside Proceeds enable Celea to initiate SURPASS-IPF, the first head-to-head Phase 3 trial in IPF, evaluating superiority of deupirfenidone as a potential new standard of care Pure